- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06133972
Fase 3 utvidelsesstudie for å evaluere langsiktig sikkerhet for Ianalumab hos deltakere med systemisk lupus erythematosus (SIRIUS-SLE forlengelse). (SIRIUS-SLE LTE)
A Randomized, Double-blind, Placebo-controlled Extension Study, Followed by a Study Treatment Withdrawal or Open-label Period, to Assess the Long-term Safety and Tolerability of Ianalumab in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE Extension)
The purpose of this study is to evaluate long-term safety and tolerability of ianalumab in participants with systemic lupus erythematosus who have previously completed the treatment period in one of the two SIRIUS-SLE core studies (CVAY736F12301 or CVAY736F12302).
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
The purpose of this extension study is to evaluate long-term safety and tolerability of ianalumab administered s.c. monthly or quarterly, compared to monthly placebo, in adolescent and adult participants with anti-nuclear antibody (ANA)-positive systemic lupus erythematosus of moderate-to-severe disease activity, who have completed either CVAY736F12301 (SIRIUS-SLE 1) or CVAY736F12302 (SIRIUS-SLE 2) core studies.
This extension study will last up to 7 years and includes the following three treatment periods:
- a 3-year double-blind, randomized, placebo-controlled treatment period, evaluating the safety and efficacy of ianalumab or placebo (Period 1);
- followed by a 2-year treatment period evaluating safety and efficacy of treatment withdrawal and open-label ianalumab administered s.c. monthly.
- and an up to 2-year open-label, safety monitoring period (Period 3).
Studietype
Registrering (Antatt)
Fase
- Fase 3
Utvidet tilgang
Kontakter og plasseringer
Studiekontakt
- Navn: Novartis Pharmaceuticals
- Telefonnummer: 1-888-669-6682
- E-post: novartis.email@novartis.com
Studer Kontakt Backup
- Navn: Novartis Pharmaceuticals
- Telefonnummer: +41613241111
- E-post: novartis.email@novartis.com
Studiesteder
-
-
-
Caba, Argentina, C1015ABO
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
Caba, Argentina, C1427CCL
- Rekruttering
- Novartis Investigative Site
-
San Miguel de Tucumán, Argentina, T4000AXL
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
-
Buenos Aires
-
La Plata, Buenos Aires, Argentina, B1900AWT
- Rekruttering
- Novartis Investigative Site
-
Quilmes, Buenos Aires, Argentina, 1878
- Rekruttering
- Novartis Investigative Site
-
San Miguel, Buenos Aires, Argentina, B1663GKT
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
-
Tucumán Province
-
San Miguel, Tucumán Province, Argentina, T4000CBC
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
-
-
-
Queensland
-
Maroochydore, Queensland, Australia, 4558
- Rekruttering
- Novartis Investigative Site
-
-
-
-
-
Salvador, Brasil, 40323-010
- Rekruttering
- Novartis Investigative Site
-
-
Espírito Santo
-
Vitória, Espírito Santo, Brasil, 29055-450
- Rekruttering
- Novartis Investigative Site
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, Brasil, 40150-150
- Rekruttering
- Novartis Investigative Site
-
-
Minas Gerais
-
Belo Horizonte, Minas Gerais, Brasil, 30150-221
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
-
Paraná
-
Curitiba, Paraná, Brasil, 80030-110
- Rekruttering
- Novartis Investigative Site
-
-
Rio de Janeiro
-
Niterói, Rio de Janeiro, Brasil, 24020-096
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
Rio de Janeiro, Rio de Janeiro, Brasil, 22211-230
- Rekruttering
- Novartis Investigative Site
-
-
São Paulo
-
Barretos, São Paulo, Brasil, 14784-400
- Rekruttering
- Novartis Investigative Site
-
São Paulo, São Paulo, Brasil, 04038-002
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
São Paulo, São Paulo, Brasil, 01244-030
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
-
-
-
-
Sofia, Bulgaria, 1431
- Rekruttering
- Novartis Investigative Site
-
-
Bulgaria
-
Plovdiv, Bulgaria, Bulgaria, 4002
- Rekruttering
- Novartis Investigative Site
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 1L7
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
-
Ontario
-
Toronto, Ontario, Canada, M5T 2S8
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
-
Quebec
-
Rimouski, Quebec, Canada, G5L 5T1
- Rekruttering
- Novartis Investigative Site
-
-
-
-
Los Ríos Region
-
Valdivia, Los Ríos Region, Chile, 5110683
- Rekruttering
- Novartis Investigative Site
-
-
RM
-
Santiago, RM, Chile, 7500588
- Rekruttering
- Novartis Investigative Site
-
-
Santiago Metropolitan
-
Santiago, Santiago Metropolitan, Chile, 7500710
- Rekruttering
- Novartis Investigative Site
-
-
-
-
-
Bogotá, Colombia, 111211
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
-
Antioquia
-
Medellín, Antioquia, Colombia, 050001
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
-
Atlántico
-
Barranquilla, Atlántico, Colombia, 080020
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
-
Cundinamarca
-
Chía, Cundinamarca, Colombia, 250001
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
-
Santander Department
-
Bucaramanga, Santander Department, Colombia, 680003
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
-
Valle del Cauca Department
-
Cali, Valle del Cauca Department, Colombia, 760046
- Rekruttering
- Novartis Investigative Site
-
-
-
-
Alabama
-
Anniston, Alabama, Forente stater, 36207
- Rekruttering
- Pinnacle Research Group Llc
-
Hovedetterforsker:
- Vishala L Chindalore
-
Ta kontakt med:
- Ruby Fields
- Telefonnummer: +1 256 236 0055
- E-post: rfields@pinnacletrials.com
-
-
California
-
Burbank, California, Forente stater, 91505
- Rekruttering
- Providence Medical Center
-
Hovedetterforsker:
- Sue Chung
-
Ta kontakt med:
- Sandra Figueroa
- Telefonnummer: +1 818 869 7067
- E-post: Sandra.Figueroa@providence.org
-
La Palma, California, Forente stater, 90623
- Rekruttering
- Advanced Medical Research
-
Hovedetterforsker:
- Gerald Ho
-
Ta kontakt med:
- Reza Azadegan
- Telefonnummer: +1 714 752 6587
- E-post: razadegan@advmedresearch.com
-
Westlake Village, California, Forente stater, 91361
- Aktiv, ikke rekrutterende
- Millennium Clinical Trials
-
-
Colorado
-
Aurora, Colorado, Forente stater, 80045
- Rekruttering
- University of Colorado Denver
-
Hovedetterforsker:
- Christopher Striebich
-
Ta kontakt med:
- Chong Pedrick
- E-post: chong.pedrick@cuanschutz.edu
-
-
Florida
-
Clearwater, Florida, Forente stater, 33765
- Rekruttering
- Clinical Res Of W Florida
-
Hovedetterforsker:
- Robert Levin
-
Ta kontakt med:
- Jessica Mayfield
- Telefonnummer: +1 727 466 0078
- E-post: JMayfield@crwf.com
-
Cooper City, Florida, Forente stater, 33024
- Rekruttering
- GNP Research
-
Hovedetterforsker:
- Mark Jaffe
-
Ta kontakt med:
- Melissa Pierce
- Telefonnummer: +1 754 248 3589
- E-post: melissa@gnpresearch.com
-
Homestead, Florida, Forente stater, 33033
- Rekruttering
- Homestead Assoc In Research Inc
-
Hovedetterforsker:
- Gilberto Seco
-
Ta kontakt med:
- Mario Hernandez
- Telefonnummer: 13052460873
- E-post: mhernandez@associatesinresearch.com
-
Plantation, Florida, Forente stater, 33324
- Rekruttering
- IRIS Research and Development
-
Hovedetterforsker:
- Guillermo Valenzuela
-
Ta kontakt med:
- Jhon Galindo
- Telefonnummer: +1 954 476 2338
- E-post: jgalindo@irisrheumatology.com
-
Tampa, Florida, Forente stater, 33603
- Rekruttering
- Clinical Research of West Florida Inc
-
Hovedetterforsker:
- John Carter
-
Ta kontakt med:
- Abby Carlson
- Telefonnummer: +1 813 870 1292
- E-post: ACarlson@crwf.com
-
-
Georgia
-
Lawrenceville, Georgia, Forente stater, 30044
- Rekruttering
- Parris and Associates Rheumatology
-
Hovedetterforsker:
- Glenn Parris
-
Ta kontakt med:
- Mannai Coutermarsh
- Telefonnummer: +17709621616#8334
- E-post: m.coutermarsh@parrisandassociates.net
-
-
Illinois
-
Skokie, Illinois, Forente stater, 60076
- Fullført
- Robert A Hozman MD SC
-
Willowbrook, Illinois, Forente stater, 60527
- Rekruttering
- Willow Rheumatology Wellness
-
Hovedetterforsker:
- Angela R Crowley
-
Ta kontakt med:
- Lubna Ali
- E-post: lali@willowrheum.com
-
-
Louisiana
-
Lake Charles, Louisiana, Forente stater, 70601
- Rekruttering
- Accurate Clinical Research
-
Hovedetterforsker:
- Enrique Mendez
-
Ta kontakt med:
- Machell Broussard
- E-post: mbroussard@accurateclinicalresearch.com
-
New Orleans, Louisiana, Forente stater, 70112
- Aktiv, ikke rekrutterende
- UMC New Orleans
-
-
Maryland
-
Baltimore, Maryland, Forente stater, 21201
- Aktiv, ikke rekrutterende
- University Of Maryland
-
-
Michigan
-
Detroit, Michigan, Forente stater, 48202
- Rekruttering
- Henry Ford Health
-
Hovedetterforsker:
- Alireza Meysami
-
Ta kontakt med:
- Jenna Hudy
- Telefonnummer: +1 313 916 1984
- E-post: jhudy1@hfhs.org
-
Grand Blanc, Michigan, Forente stater, 48439
- Rekruttering
- Ahmed Arif Medical Research Center
-
Hovedetterforsker:
- Ali Karrar
-
Ta kontakt med:
- Iman Abdelrahman
- Telefonnummer: +1 810 953 8700
- E-post: iman@aamrc.net
-
-
Ohio
-
Middleburg Heights, Ohio, Forente stater, 44130
- Rekruttering
- Paramount Med Rsrch and Consult LLC
-
Hovedetterforsker:
- Isam Diab
-
Ta kontakt med:
- Denine Ryan
- Telefonnummer: +1 440 891 9395
- E-post: deniner64@gmail.com
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Forente stater, 15213
- Rekruttering
- University Of Pittsburgh
-
Hovedetterforsker:
- Andreea Coca
-
Ta kontakt med:
- Kathryn Lemon
- E-post: kal128@pitt.edu
-
-
Tennessee
-
Jackson, Tennessee, Forente stater, 38305
- Rekruttering
- West Tennessee Research Institute
-
Hovedetterforsker:
- Jacob A Aelion
-
Ta kontakt med:
- Rachel Williams
- Telefonnummer: 17316330119
- E-post: rwilliams@arthritisclinic.org
-
Memphis, Tennessee, Forente stater, 38119
- Rekruttering
- Shelby Research LLC
-
Hovedetterforsker:
- Ramesh C Gupta
-
Ta kontakt med:
- Suvarna Konangula
- Telefonnummer: +1 901 681 9670
- E-post: shelbyres1999@outlook.com
-
-
Texas
-
Bellaire, Texas, Forente stater, 77401
- Rekruttering
- Novel Research LLC
-
Hovedetterforsker:
- Wajeeha Yousaf
-
Ta kontakt med:
- Hassan Khan
- E-post: khan@novelresearch.net
-
League City, Texas, Forente stater, 77573
- Rekruttering
- Accurate Clinical Research
-
Hovedetterforsker:
- Sabeen Najam
-
Ta kontakt med:
- Mariela Martinez
- Telefonnummer: +1 281 422 7179
- E-post: mmartinez@accurateclinicalresearch.com
-
Red Oak, Texas, Forente stater, 75154
- Rekruttering
- Epic Medical Research
-
Hovedetterforsker:
- Sunny Patel
-
Ta kontakt med:
- Harshini Potluri
- Telefonnummer: +1 469 206 2642
- E-post: hpotluri@epicmedresearch.com
-
-
-
-
-
Montpellier, Frankrike, 34295
- Rekruttering
- Novartis Investigative Site
-
Paris, Frankrike, 75014
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
Paris, Frankrike, 75013
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
Toulouse, Frankrike, 31059
- Rekruttering
- Novartis Investigative Site
-
Toulouse, Frankrike, 31054
- Rekruttering
- Novartis Investigative Site
-
-
-
-
-
Guatemala City, Guatemala, 01010
- Rekruttering
- Novartis Investigative Site
-
-
Departamento de Guatemala
-
Guatemala City, Departamento de Guatemala, Guatemala, 01010
- Rekruttering
- Novartis Investigative Site
-
-
-
-
-
New Delhi, India, 110075
- Rekruttering
- Novartis Investigative Site
-
-
Gujarat
-
Ahmedabad, Gujarat, India, 380015
- Rekruttering
- Novartis Investigative Site
-
Ahmedabad, Gujarat, India, 380006
- Rekruttering
- Novartis Investigative Site
-
-
Kerala
-
Kozhikode, Kerala, India, 673008
- Rekruttering
- Novartis Investigative Site
-
-
Maharashtra
-
Kolhāpur, Maharashtra, India, 416001
- Rekruttering
- Novartis Investigative Site
-
Nagpur, Maharashtra, India, 441108
- Rekruttering
- Novartis Investigative Site
-
Nashik, Maharashtra, India, 422101
- Rekruttering
- Novartis Investigative Site
-
Pune, Maharashtra, India, 411001
- Rekruttering
- Novartis Investigative Site
-
Pune, Maharashtra, India, 411007
- Rekruttering
- Novartis Investigative Site
-
-
National Capital Territory of Delhi
-
New Delhi, National Capital Territory of Delhi, India, 110060
- Rekruttering
- Novartis Investigative Site
-
-
New Delhi
-
New Delhi, New Delhi, India, 110029
- Rekruttering
- Novartis Investigative Site
-
-
Uttarakhand
-
Dehradun, Uttarakhand, India, 248001
- Rekruttering
- Novartis Investigative Site
-
-
-
-
-
Haifa, Israel, 3109601
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
Ramat Gan, Israel, 5265601
- Rekruttering
- Novartis Investigative Site
-
-
-
-
FE
-
Cona, FE, Italia, 44124
- Rekruttering
- Novartis Investigative Site
-
-
PD
-
Padova, PD, Italia, 35128
- Rekruttering
- Novartis Investigative Site
-
-
PI
-
Pisa, PI, Italia, 56126
- Rekruttering
- Novartis Investigative Site
-
-
RM
-
Roma, RM, Italia, 00152
- Rekruttering
- Novartis Investigative Site
-
-
TO
-
Torino, TO, Italia, 10128
- Rekruttering
- Novartis Investigative Site
-
-
-
-
-
Miyazaki, Japan, 8891692
- Rekruttering
- Novartis Investigative Site
-
Osaka, Japan, 5458586
- Rekruttering
- Novartis Investigative Site
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Japan, 4578510
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
Nagoya, Aichi-ken, Japan, 4578511
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
-
Hokkaido
-
Sapporo, Hokkaido, Japan, 0608648
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
-
Kanagawa
-
Yokohama, Kanagawa, Japan, 2360004
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
-
Miyagi
-
Sendai, Miyagi, Japan, 9838512
- Rekruttering
- Novartis Investigative Site
-
-
Tokyo
-
Bunkyo-ku, Tokyo, Japan, 1138519
- Rekruttering
- Novartis Investigative Site
-
Chuo Ku, Tokyo, Japan, 1048560
- Rekruttering
- Novartis Investigative Site
-
Fuchū, Tokyo, Japan, 1838524
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
Shinjuku-ku, Tokyo, Japan, 1608582
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
tabashi City, Tokyo, Japan, 1738610
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
-
-
-
-
Beijing, Kina, 100730
- Rekruttering
- Novartis Investigative Site
-
Beijing, Kina, 100069
- Rekruttering
- Novartis Investigative Site
-
Shanghai, Kina, 200001
- Rekruttering
- Novartis Investigative Site
-
Xinxiang, Kina, 453099
- Rekruttering
- Novartis Investigative Site
-
-
Guangdong
-
Guangzhou, Guangdong, Kina, 510080
- Rekruttering
- Novartis Investigative Site
-
Guangzhou, Guangdong, Kina, 510000
- Rekruttering
- Novartis Investigative Site
-
Shantou, Guangdong, Kina, 515000
- Rekruttering
- Novartis Investigative Site
-
-
Jiangsu
-
Nanjing, Jiangsu, Kina, 210008
- Rekruttering
- Novartis Investigative Site
-
Suzhou, Jiangsu, Kina, 215004
- Rekruttering
- Novartis Investigative Site
-
-
Jiangxi
-
Nanchang, Jiangxi, Kina, 330006
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
Pingxiang, Jiangxi, Kina, 337000
- Rekruttering
- Novartis Investigative Site
-
-
Jilin
-
Changchun, Jilin, Kina, 130021
- Rekruttering
- Novartis Investigative Site
-
-
Shandong
-
Linyi, Shandong, Kina, 276100
- Rekruttering
- Novartis Investigative Site
-
-
Sichuan
-
Chengdu, Sichuan, Kina, 610041
- Rekruttering
- Novartis Investigative Site
-
-
Xinjiang
-
Ürümqi, Xinjiang, Kina, 830001
- Rekruttering
- Novartis Investigative Site
-
-
Zhejiang
-
Ningbo, Zhejiang, Kina, 315016
- Rekruttering
- Novartis Investigative Site
-
Wenzhou, Zhejiang, Kina, 325000
- Rekruttering
- Novartis Investigative Site
-
-
-
-
Perak
-
Ipoh, Perak, Malaysia, 30450
- Rekruttering
- Novartis Investigative Site
-
-
-
-
-
México, Mexico, 07760
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
-
Guanajuato
-
León, Guanajuato, Mexico, 37160
- Rekruttering
- Novartis Investigative Site
-
-
Jalisco
-
Guadalajara, Jalisco, Mexico, 44160
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
-
Mexico City
-
Mexico City, Mexico City, Mexico, 06700
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
-
Michoacán
-
Morelia, Michoacán, Mexico, 58000
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
-
Yucatán
-
Mérida, Yucatán, Mexico, 97070
- Rekruttering
- Novartis Investigative Site
-
-
-
-
-
Bydgoszcz, Polen, 85-065
- Rekruttering
- Novartis Investigative Site
-
Bydgoszcz, Polen, 85-168
- Rekruttering
- Novartis Investigative Site
-
Bytom, Polen, 41 902
- Rekruttering
- Novartis Investigative Site
-
Warsaw, Polen, 00-874
- Rekruttering
- Novartis Investigative Site
-
Warsaw, Polen, 04-141
- Rekruttering
- Novartis Investigative Site
-
-
Lower Silesian Voivodeship
-
Wroclaw, Lower Silesian Voivodeship, Polen, 52-210
- Rekruttering
- Novartis Investigative Site
-
-
-
-
-
Braga, Portugal, 4710-243
- Rekruttering
- Novartis Investigative Site
-
Lisbon, Portugal, 1050-034
- Rekruttering
- Novartis Investigative Site
-
-
-
-
-
Brasov, Romania, 500283
- Rekruttering
- Novartis Investigative Site
-
Bucharest, Romania, 011172
- Rekruttering
- Novartis Investigative Site
-
-
Cluj
-
Cluj-Napoca, Cluj, Romania, 400006
- Rekruttering
- Novartis Investigative Site
-
-
-
-
-
Bratislava, Slovakia, 811 08
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
Košice, Slovakia, 040 01
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
-
-
-
-
Barcelona, Spania, 08035
- Rekruttering
- Novartis Investigative Site
-
Madrid, Spania, 28034
- Rekruttering
- Novartis Investigative Site
-
Valencia, Spania, 46014
- Rekruttering
- Novartis Investigative Site
-
-
A Coruna
-
Santiago Compostela, A Coruna, Spania, 15706
- Rekruttering
- Novartis Investigative Site
-
-
Barcelona
-
Badalona, Barcelona, Spania, 08916
- Rekruttering
- Novartis Investigative Site
-
-
Cantabria
-
Santander, Cantabria, Spania, 39008
- Rekruttering
- Novartis Investigative Site
-
-
Catalonia
-
Barcelona, Catalonia, Spania, 08003
- Rekruttering
- Novartis Investigative Site
-
-
Madrid
-
San Sebastian Reyes, Madrid, Spania, 28702
- Rekruttering
- Novartis Investigative Site
-
-
-
-
-
Gwangju, Sør -Korea, 61469
- Fullført
- Novartis Investigative Site
-
Seoul, Sør -Korea, 06591
- Rekruttering
- Novartis Investigative Site
-
Seoul, Sør -Korea, 04763
- Rekruttering
- Novartis Investigative Site
-
-
-
-
-
Umhlanga, Sør-Afrika, 4320
- Rekruttering
- Novartis Investigative Site
-
-
Gauteng
-
Pretoria, Gauteng, Sør-Afrika, 0002
- Rekruttering
- Novartis Investigative Site
-
-
Western Cape
-
Cape Town, Western Cape, Sør-Afrika, 7500
- Rekruttering
- Novartis Investigative Site
-
Cape Town, Western Cape, Sør-Afrika, 7405
- Rekruttering
- Novartis Investigative Site
-
Somerset West, Western Cape, Sør-Afrika, 7130
- Rekruttering
- Novartis Investigative Site
-
-
-
-
-
Kaohsiung City, Taiwan, 833
- Rekruttering
- Novartis Investigative Site
-
Taichung, Taiwan, 40447
- Rekruttering
- Novartis Investigative Site
-
Taichung, Taiwan, 407219
- Rekruttering
- Novartis Investigative Site
-
Taipei, Taiwan, 10002
- Rekruttering
- Novartis Investigative Site
-
Taipei, Taiwan, 11217
- Rekruttering
- Novartis Investigative Site
-
Taoyuan, Taiwan, 33305
- Rekruttering
- Novartis Investigative Site
-
-
-
-
-
Bangkok, Thailand, 10400
- Rekruttering
- Novartis Investigative Site
-
Bangkok, Thailand, 10700
- Rekruttering
- Novartis Investigative Site
-
-
Hat Yai
-
Songkhla, Hat Yai, Thailand, 90110
- Rekruttering
- Novartis Investigative Site
-
-
Thailand
-
Muang, Thailand, Thailand, 12120
- Rekruttering
- Novartis Investigative Site
-
-
-
-
-
Brno, Tsjekkia, 638 00
- Rekruttering
- Novartis Investigative Site
-
Prague, Tsjekkia, 128 00
- Rekruttering
- Novartis Investigative Site
-
Uherské Hradiště, Tsjekkia, 686 01
- Rekruttering
- Novartis Investigative Site
-
-
-
-
North Rhine-Westphalia
-
Cologne, North Rhine-Westphalia, Tyskland, 50937
- Tilbaketrukket
- Novartis Investigative Site
-
-
Saxony
-
Leipzig, Saxony, Tyskland, 04103
- Rekruttering
- Novartis Investigative Site
-
-
-
-
-
Budapest, Ungarn, 1134
- Rekruttering
- Novartis Investigative Site
-
Gyula, Ungarn, 5700
- Rekruttering
- Novartis Investigative Site
-
Zalaegerszeg, Ungarn, 8900
- Rekruttering
- Novartis Investigative Site
-
-
Fejér
-
Székesfehérvár, Fejér, Ungarn, 8000
- Rekruttering
- Novartis Investigative Site
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Key Inclusion Criteria:
- Signed informed consent prior to participation in the extension study. Parent or legal guardian's signed informed consent and child's assent, if appropriate, are required before any assessment is performed for participants <18 years of age. Of note, if the participant reaches age of consent (age as per local law) during the study, they will also need to sign the corresponding study Informed Consent Form (ICF) at the next study visit.
- Participants must have participated in either one of the two SIRIUS-SLE core studies, CVAY736F12301 or CVAY736F12302, and have completed the treatment period through Week 60 without treatment discontinuation.
- In the judgement of the investigator, participants must be expected to clinically benefit from continued study treatment.
Key Exclusion Criteria:
- Use of prohibited therapies.
- Active viral, bacterial or other infections requiring intravenous or intramuscular treatment for clinically significant infection which in the opinion of the investigator will place the participant at risk for participation.
- Plans for administration of live vaccines during the study period.
- Pregnant or nursing (lactating) women.
Other protocol-defined inclusion/exclusion criteria may apply.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Ianalumab monthly
Ianalumab s.c. monthly |
Ianalumab s.c. monthly Ianalumab s.c. quarterly
Andre navn:
|
|
Eksperimentell: Ianalumab quarterly
Ianalumab s.c. quarterly |
Ianalumab s.c. monthly Ianalumab s.c. quarterly
Andre navn:
|
|
Placebo komparator: Placebo monthly
Placebo s.c. monthly |
Placebo s.c. monthly |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of treatment-emergent Adverse events/Serious Adverse events
Tidsramme: through study completion, up to approximately 324 weeks
|
Assessment of long-term safety and tolerability of ianalumab |
through study completion, up to approximately 324 weeks
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Proportion of participants who achieved Systemic Lupus Erythematosus Responder Index -4 (SRI-4) response
Tidsramme: up to Week 324
|
SRI-4 response is defined as:
|
up to Week 324
|
|
Proportion of participants who achieved Definition of Remission in SLE (DORIS) response
Tidsramme: up to Week 324
|
DORIS is defined as:
|
up to Week 324
|
|
Change in Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index
Tidsramme: up to Week 324
|
SLICC/ACR Damage Index is a measure of cumulative damage due to SLE |
up to Week 324
|
|
Average daily dose of corticosteroids administered
Tidsramme: up to Week 324
|
Evaluating the effect of ianalumab on corticosteroids intake |
up to Week 324
|
|
Annualized BILAG moderate or severe flare rate
Tidsramme: up to Week 324
|
Annualized BILAG moderate or severe flare rate where moderate BILAG flare is defined as 2 or more new BILAG-2004 B items, and severe BILAG flare is defined as 1 or more new BILAG-2004 A items, compared to the previous visit |
up to Week 324
|
|
Ianalumab serum concentrations during treatment and follow-up after last dose
Tidsramme: up to Week 324
|
To characterize the Pharmacokinetics (PK) of ianalumab |
up to Week 324
|
|
Incidence and titer of anti-ianalumab antibodies in serum (ADA assay) over time.
Tidsramme: up to Week 324
|
To characterize the immunogenicity of ianalumab |
up to Week 324
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- CVAY736F12301E1
- 2023-505929-14-00 (Registeridentifikator: EU CT NUMBER)
- 2023 (U.S. NIH-stipend/kontrakt)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .